genglob magazine

Icon

magazine by genglob.com for generics, medicines and alternative treatments like ayurveda and traditional chinese

Indian court to rule on generic drug industry

From Africa’s crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India’s drug companies can continue to provide cheap versions of many life-saving medicines.

The case — involving Swiss drug maker Novartis AG’s cancer drug Glivec — pits aid groups that argue India plays a vital role as the pharmacy to the poor against drug companies that insist they need strong patents to make drug development profitable. A ruling by India’s Supreme Court is expected in early 2013. Read the rest of this entry »

Share

Late Effects and Healthy Living: Lessons for Childhood Cancer Survivors

Once childhood cancer patients have been declared cancer-free, most are not completely out of the woods. More than 60 percent of childhood cancer survivors experience late effects of cancer treatment resulting in chronic conditions. The New England Journal of Medicine says nearly half of all late effects are severe, life threatening or disabling.

Although two-thirds of all childhood cancer survivors develop late effects—including breast cancer, heart disease, learning disabilities, infertility and hearing loss—few get adequate follow-up care.

“Most of them don’t know their risks for medical late effects, which puts them in a very precarious position in terms of maintaining their health,” says Nancy Keene, a parent of a survivor of childhood leukemia, and author of topical books including “Childhood Cancer Survivors: A Practical Guide to Your Future.” Read the rest of this entry »

Share

Three Ways to Reduce Exposure to Cell Phone Radiation

Five words or less

The debate about radiation exposure from cell phone use still doesn’t have a conclusive answer, but the World Health Organization (WHO) classified cell phone radiation as a “potential carcinogen” alongside other hazards like lead, engine exhaust and chloroform. That means prolonged cell phone use can possibly increase the risk of specific types of brain cancer and tumor growth, according to WHO.
Although international research, such as the noted Interphone study conducted by the International Agency for Research on Cancer, continues to be somewhat contradictory, experts agree consumers have reason for concern, particularly heavy users and youth. Read the rest of this entry »
Share

Indian Government allow legal generic cancer drug under TRIPS

India’s government for the first time will allow a generic-drug maker to produce and sell cheaper copies of a patented cancer medicine, a decision that pressures brand-name manufacturers to lower prices.Sorafenib - nexavar

Natco Pharma Ltd. (NTCPH) received a so-called compulsory license to make Bayer AG (BAYN)’s Nexavar, which goes by the generic name sorafenib, and will have to sell it at a 97 percent discount to Bayer’s existing product, India’s Controller General of Patents Designs and Trademarks said yesterday in a statement on its website. Read the rest of this entry »

Share

NATCO confirms filing of ANDA for Generic Revlimid

Hyderabad based NATCO Pharma Limited today confirmed that the company has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market lenalidomide capsules in 5, 10, 15 and 25mg strengths prior to the expiration of various U.S. patents. NATCO’s lenalidomide capsules are the generic version of Celgene Corporation’s Revlimid®.

On August 30, 2010, pursuant to the Hatch-Waxman Act, NATCO notified Celgene that its ANDA requesting approval from the FDA for a generic version of Revlimid® contained a paragraph IV certification asserting that various Revlimid® patents are invalid, unenforceable and/or not infringed. Lenalidomide, which is presently marketed as Revlimid by Celgene, is a derivative of thalidomide and is used in the treatment for multiple myeloma. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Read the rest of this entry »

Share

Breast Cancer Gene Patents Struck Down

A biotechnology company that holds patents on the BRCA1 and BRCA2 genes may lose them after a federal judge ruled that seven of their 23 patents involving the genes tied to breast and ovarian cancers should not have been granted, the New York Times reports. The American Civil Liberties Union and the Public Patent Foundation filed a suit last year, claiming that patents held by Myriad Genetics kept competitors from creating tests to find mutations in the genes and stifled research.If the court’s decision is upheld, the biotechnology industry would “have to get more creative about how to retain exclusivity and attract capital in the face of potentially weaker patent protection,” said Kenneth Chahine, who filed an amicus brief for Myriad, the Times reports. Read the rest of this entry »

Share

cost of cancer treatment $618,616 – Amanda Bennet’s story

Kidney Cancer and renal systemAfter 2 years of her husband’s death Amanda Bennet examines the cost of keeping one man alive suffering from cancer. Read the rest of this entry »

Share

sales of generics continue to climb

THE GLOBAL generic drug industry has witnessed an almost decade-long sales euphoria and volumes and sales growth of prescription generic drugs continued to increase in 2009.

In the 12 months ended September 2009, global prescription sales growth of generic drugs climbed by 7.7%, up from 3.6% in 2008, according to US-based health care information and consulting company IMS Health. This compares with the 5.7% growth seen within the overall global pharmaceutical universe last year, says Doug Long, vice-president, industry relations at IMS Health. Read the rest of this entry »

Share

ovarian cancer and influence of diet on survival

Ovarian Cancer2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical. A study published in the March 2010 issue of the Journal of the American Dietetic Association, is among the first to evaluate possible diet associations with ovarian cancer survival. Researchers from the University of Illinois at Chicago determined that there is a strong relationship between healthy eating and prolonged survival. Read the rest of this entry »

Share

pomegranate and cancer

Eating pomegranates or drinking pomegranate juice may help prevent and slow the growth of some types of breast cancer. A new study shows a group of phytochemicals called ellagitannins found in abundance in pomegranates inhibited the growth of estrogen-responsive breast cancer in laboratory tests. Read the rest of this entry »

Share